{"groups":[{"description":"30 mg three days a week (Mondays, Wednesdays and Fridays).\n\n1 cycle was 28 days\n\nDose modifications for attributable toxicities allowed for reduction to:\n\n* 25 mg, 20 mg three times a week every week\n* Or 20 mg three times a week every other week. No dose re-escalation was allowed.\n\n  * The protocol was amended on 6/15/2010 because of concerns of toxicity to allow a starting dose of 25 mg; 12/36 (33%) patients were enrolled on the 25 mg dose.\n\nLBH589","id":"FG000","title":"LBH589"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Progressive Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"22"}],"type":"New Systemic Therapy"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Still on Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"7"}],"type":"Still on Active Therapy"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Ineligible for Study Drug"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"39"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"36"}],"comment":"3 patients deemed ineligible","type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"12"}],"comment":"Protocol Amendment 6/15/2010. Study drug starting dose reduced.","type":"Starting Dose Reduction: 30 mg to 25 mg"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"comment":"Since treatment was not of fixed duration, all participants were considered as 'Not Completed' and reason off-treatment is provided.","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"39"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"From July 2009 to March 2011"}